AVANOS MEDICAL, INC. financials

AVNS CIK 0001606498

Source: EDGAR filings · Built 2026-06-02T02:24:09Z

Custom taxonomy namespace: ffd

Key metrics by reporting period

Up to six most-recent periods side-by-side. Rows are the curated key lines — revenue, margins, cash, debt, equity, cash-flow totals, plus the derived and valuation metrics we compute on top. For every tag a filer reported in one period, use the single-filing drilldown below.

Derived Metrics

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Free Cash Flow 43.10M 82.90M 14.60M 71.60M 66.30M -22.70M
EBITDA -22.70M -350.70M 50.30M 83.20M -700.00K -5.60M
Working Capital 190.20M 227.50M 252.40M 433.10M 288.40M 300.90M
Net Debt 29.10M 53.10M 112.80M 149.30M 69.00M 137.30M
Gross Margin 50.47% 55.44% 56.39% 57.62% 50.97% 51.89%
Operating Margin -8.78% -57.60% 0.62% 5.19% -6.64% -6.79%
Net Margin -10.40% -57.01% -9.18% 7.38% 1.07% -4.06%
Return on Equity (ROE) -9.37% -47.33% -5.00% 3.91% 0.50% -2.30%
Return on Assets (ROA) -6.79% -33.97% -3.65% 2.83% 0.39% -1.73%
Current Ratio 2.15× 2.37× 2.08× 3.27× 3.07× 2.81×
Debt-to-Equity 0.15× 0.19× 0.16× 0.21× 0.15× 0.20×
Effective Tax Rate -10.12% 4.22% -25.32% 19.48% 26.60% 53.90%
Cash Conversion Ratio -1.02× -0.26× -0.52× 1.80× 13.86× 0.09×
Accruals Ratio -0.14× -0.43× -0.06× -0.02× -0.05× -0.02×
SBC % of Revenue 1.80% 2.01% 2.35% 2.32% 2.25% 1.69%
CapEx Coverage 2.36× 5.66× 1.82× 4.71× 4.16× -0.12×
Free Cash Flow Per Share $0.93 $1.80 $0.31 $1.51 $1.36 $-0.47

Valuation Metrics

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
P/E Trailing (Diluted) 25.29× 266.69×
P/FCF 12.06× 8.83× 71.59× 17.88× 25.41×
FCF Yield 8.29% 11.32% 1.40% 5.59% 3.93%
EV / EBITDA 22.83× 16.93×
P/S 0.74× 1.06× 1.54× 1.84× 2.85× 3.08×
P/B 0.67× 0.88× 0.84× 0.98× 1.32× 1.74×

Income Statement

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Revenue from Contract with Customer, Excluding Assessed Tax 701.20M 687.80M 673.30M 684.10M 587.00M 714.80M
Cost of Goods and Services Sold 347.30M 306.50M 293.60M 289.90M 287.80M 343.90M
Gross Profit 353.90M 381.30M 379.70M 394.20M 299.20M 370.90M
Research and Development Expense 23.30M 26.20M 27.20M 29.20M 30.60M 34.90M
Selling, General and Administrative Expense 315.60M 318.50M 335.00M 326.50M 285.30M 332.60M
Operating Income (Loss) -61.60M -396.20M 4.20M 35.50M -39.00M -48.50M
Income Tax Expense (Benefit) 6.70M -17.00M 2.00M 5.20M -11.20M -33.90M
Net Income (Loss) Attributable to Parent -72.90M -392.10M -61.80M 50.50M 6.30M -29.00M
Earnings Per Share, Basic $-1.57 $-8.53 $-1.32 $1.08 $0.13 $-0.61
Weighted Average Number of Shares Outstanding, Basic 46.30M 46.00M 46.60M 46.90M 48.10M 47.80M
Earnings Per Share, Diluted $-1.57 $-8.53 $-1.32 $1.07 $0.13 $-0.61
Weighted Average Number of Shares Outstanding, Diluted 46.30M 46.00M 46.60M 47.30M 48.60M 47.80M

Balance Sheet

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Cash and Cash Equivalents, at Carrying Value 89.80M 107.70M 87.70M 127.70M 118.50M 111.50M
Assets, Current 355.40M 393.40M 487.00M 624.10M 427.60M 467.20M
Assets 1.07B 1.15B 1.69B 1.79B 1.60B 1.67B
Long-term Debt 90.30M 125.30M 159.40M 226.30M 130.00M 180.00M
Liabilities, Current 165.20M 165.90M 234.60M 191.00M 139.20M 166.30M
Long-term Debt, Excluding Current Maturities 226.30M 130.00M
Liabilities 295.50M 325.70M 456.10M 495.70M 333.00M 416.30M
Stockholders' Equity Attributable to Parent 778.20M 828.50M 1.24B 1.29B 1.27B 1.26B
Common Stock, Shares, Outstanding 46.46M 45.96M 46.17M 46.53M 48.21M 47.92M

Cash Flow Statement

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Net Cash Provided by (Used in) Operating Activities 74.70M 100.70M 32.40M 90.90M 87.30M -2.50M
Net Cash Provided by (Used in) Investing Activities -60.60M -27.50M 21.60M -135.40M -21.00M -24.20M
Payments for Repurchase of Common Stock 3.30M 12.80M 19.10M 45.50M 11.50M 900.00K
Net Cash Provided by (Used in) Financing Activities -37.00M -49.10M -94.20M 56.70M -55.30M -70.00M

Raw XBRL tagging for a single filing

Every us-gaap and custom concept the filer tagged for one fiscal period, grouped by statement. Start here when a number in the trend table above surprises you and you want to see the exact tag behind it. Derived and valuation rows are omitted here because they already appear in the trend table.

Most recent filing shown by default.

Compare filings side-by-side

Diff any two filings with deltas and added / removed tags.

Immaterial rows are USD line items under 1% of the period's revenue — the noise floor below which a single tag rarely moves the investment thesis. Revenue is read from the filer's top-line concept (Revenues / RevenueFromContractWithCustomerExcludingAssessedTax, with a fallback chain). Non-USD rows, rows without a numeric value, and every row on a filing with no identifiable revenue anchor stay visible. Flip the switch off to see every tag the filer reported for the period.

Loading filing details…

Methodology

All facts on this page come straight from SEC EDGAR XBRL company-facts filings (AVNS CIK 0001606498), grouped by financial statement using FASB's base us-gaap presentation taxonomy. Filers may re-parent concepts onto different statements in their own extension taxonomy, so a handful of rows can show up under a different statement than on the actual 10-K / 10-Q; custom concepts and any we couldn't map fall into Other. Hover a cell to see the fully-qualified concept name and the filer's description.

For the full methodology — statement grouping, the Other bucket, derived metrics, and fact tooltips — see the methodology reference for the statement grouping, the "Other" bucket, derived metrics, and fact tooltips.

Related tickers

WGS

GeneDx Holdings Corp.

ELA

Envela Corporation

NRGV

ENERGY VAULT HOLDINGS, INC.